iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Neuropathic Pain

DELAWARE, March 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings that iQ-008, a novel analgesic compound, demonstrates efficacy in in vivo studies. Developed as a therapeutic for neuropathic pain, iQ-008 shows significant effectiveness in all pain models.

A rationally designed, multi-targeting compound, iQ-008 presented a better-than-standard profile in preclinical efficacy screenings. “This is very good news and an important step in the development of iQ-008 as a promising therapeutic,” said iQure Chief Executive Officer Pawel Zolnierczyk. “The results of efficacy after oral dosing are a further indication that iQ‑008 will be viable in capsule or tablet form in human studies. We are encouraged by successful in vivo studies with the data confirming that iQ-008 meets the criteria for the Lipinski/Pfizer Rule of Five.”

Lipinski’s Rule of Five, also known as Pfizer’s Rule of Five, is a critical indicator for drug development programs that help identify successful drug candidates. The rules identify candidates likely to have a desired profile on intestinal permeability and aqueous solubility, which is an indication for oral absorption.

Earlier this year, iQure secured global patent protection (including the US, Europe, China and Canada) for iQ-008, following results showing efficacy in outperforming standards of care.

About iQure Pharma

iQure Pharma is a global biotech firm headquartered in the US, focused on the development of new therapeutics for neuropathic pain. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum

DELAWARE, March, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has been invited to present at the Mid-Atlantic Diamond Venture (MADV) Virtual Spring Forum on Friday, March 25, 2022.

Dedicated to improving the management of neuropathic pain, iQure developed iQ‑007 as a promising candidate with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with encouraging results in both neuropathic pain as well as epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a better-than-standard profile in all tested in vivo pain models.

“We are delighted to have been invited to present at this high-profile event,” said iQure Chief Executive Officer, Pawel Zolnierczyk. “This presentation helps to expand our network to an even larger group of investors from the Mid-Atlantic region and enhances our company’s ongoing fund-raising efforts.”

Mid-Atlantic Diamond Ventures (MADV) is an independent organization that assists emerging, technology-based companies in their effort to build sustainable businesses by better positioning them for funding while increasing value at an early and crucial stage.

To date, over 400 Mid-Atlantic companies have presented at MADV and have raised more than $640 million. MADV is located at the Temple University Fox School of Business and is sponsored by prestigious service firms, major angel constituencies, as well as, local economic development groups.

iQure Pharma is Investment-Ready — Will Present at Keiretsu Forum Mid-Atlantic

DELAWARE, February 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has completed its Due Diligence process with Keiretsu Mid-Atlantic as Lead Investors, with initial commitments already secured.

Dedicated to a new generation of neuropathic pain management therapeutics, iQure developed iQ-007 as a promising candidate with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with encouraging results in neuropathic pain as well as a secondary indication of epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a better-than-standard profile in all tested in vivo pain models.

“We are delighted to have the opportunity to provide an update to the Keiretsu Mid-Atlantic and South-East Chapters,” said iQure Chief Executive Officer, Pawel Zolnierczyk. "This update helps to arrange the funding required to reach the clinical stage, which will offer alternative treatment options to a large number of patients suffering from Neuropathic Pain.”

The Due Diligence process was completed successfully, and the company is now fully prepared to accept funding from investors, while offering attractive investment terms. The Angel Investor-friendly Term Sheet for Series A Preferred offers capital protection, favorable valuation, and a significant number of warrants. Company is in the process of securing $3.9MM and first commitments have already been received from members of the Due Diligence Team.